Anthony Manning Sells Shares of Monte Rosa Therapeutics
Anthony Manning sold 10,000 shares of Monte Rosa Therapeutics on June 29, 2026.
Key Points
- Anthony Manning sold 10,000 shares of Monte Rosa Therapeutics, Inc. (GLUE) on June 29, 2026.
- Shares of GLUE traded near $24.20 on Wednesday, with a market cap of about $2.04 billion.
- Analysts from Guggenheim and JP Morgan maintain 'buy' ratings with targets up to $35.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Anthony Manning sold 10,000 shares of Monte Rosa Therapeutics, Inc. (NasdaqGS: GLUE) on June 29, 2026. The transaction was not part of a pre-planned trading program. Shares of Monte Rosa traded near $24.20 on Wednesday.
Insider Buying and Selling at Monte Rosa Therapeutics, Inc.
On June 29, 2026, Anthony Manning sold 10,000 shares at an average price of $23.11. This sale was not conducted under a Rule 10b5-1 plan. Additionally, Chief Medical Officer Filip Janku sold 6,000 shares at $22.95 under a planned transaction, and separately bought 6,000 shares at $7.56.
Other Institutional Activity in Monte Rosa Therapeutics
Several institutional investors have recently adjusted their positions in Monte Rosa Therapeutics. Price T Rowe Associates Inc. increased its holdings by 1,601,284 shares, ending with 6,720,188 shares valued at approximately $110.5 million, marking a 31.3% increase. Versant Venture Management added 1,978,873 shares, bringing its total to 6,361,560 shares worth about $104.6 million, reflecting a 45.2% increase. BlackRock, Inc. also boosted its position by 1,456,523 shares to a total of 5,637,684 shares, valued at $92.7 million, a 34.8% increase.
Monte Rosa Therapeutics, Inc. Stock Up 73.6%
Shares of Monte Rosa Therapeutics, Inc. (NasdaqGS: GLUE) traded near $24.20 on Wednesday. The company has a market cap of approximately $2.04 billion and a forward P/E ratio of -13.34, indicating it is currently not profitable. The stock has experienced a 52-week range from a low of $4.12 to a high of $25.77. Monte Rosa's 50-day moving average is $19.09, and its 200-day moving average is $16.34.
$GLUE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 30, 2026, Guggenheim maintained its 'buy' rating on Monte Rosa Therapeutics with a price target of $35. Earlier, on May 11, 2026, JP Morgan also maintained a 'buy' rating with a target of $31. The consensus among analysts is a 'buy' recommendation, with an average price target of $32.33 based on six opinions.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing precision medicines using molecular glue degraders to target and degrade disease-causing proteins. Its pipeline includes treatments for MYC-driven tumors, neurological and autoimmune diseases, and several types of cancer. The company collaborates with F. Hoffmann-La Roche Ltd. and Novartis to advance its research and development efforts.
Bottom Line
Anthony Manning's recent sale of Monte Rosa Therapeutics shares is part of ongoing insider activity. Investors keep a close eye on these transactions for potential insights into company performance. Monte Rosa's stock remains a subject of interest, with analysts maintaining optimistic price targets. As always, it's important to remember that insider sales are not necessarily indicative of a company's future performance.
Get Monte Rosa Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GLUE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.